Suven Life Sciences (Suven) has secured product patents in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2031. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
With these new patents, Suven has a total of one granted product patent in ARIPO, nineteen granted patents from Europe, eighteen granted patents from Hong Kong, eighteen granted patents from Japan, seven granted patents from Macau and eighteen granted patents from South Korea.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. The products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |